These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 18359857)

  • 1. Design of an engineered N-terminal HIV-1 gp41 trimer with enhanced stability and potency.
    Dwyer JJ; Wilson KL; Martin K; Seedorff JE; Hasan A; Medinas RJ; Davison DK; Feese MD; Richter HT; Kim H; Matthews TJ; Delmedico MK
    Protein Sci; 2008 Apr; 17(4):633-43. PubMed ID: 18359857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heptad-repeat-2 mutations enhance the stability of the enfuvirtide-resistant HIV-1 gp41 hairpin structure.
    Jenwitheesuk E; Samudrala R
    Antivir Ther; 2005; 10(8):893-900. PubMed ID: 16430194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trimeric, coiled-coil extension on peptide fusion inhibitor of HIV-1 influences selection of resistance pathways.
    Zhuang M; Wang W; De Feo CJ; Vassell R; Weiss CD
    J Biol Chem; 2012 Mar; 287(11):8297-309. PubMed ID: 22235115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations That Increase the Stability of the Postfusion gp41 Conformation of the HIV-1 Envelope Glycoprotein Are Selected by both an X4 and R5 HIV-1 Virus To Escape Fusion Inhibitors Corresponding to Heptad Repeat 1 of gp41, but the gp120 Adaptive Mutations Differ between the Two Viruses.
    Zhuang M; Vassell R; Yuan C; Keller PW; Ling H; Wang W; Weiss CD
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30894471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the enfuvirtide resistance mutation N43D and the associated baseline polymorphism E137K on peptide sensitivity and six-helix bundle structure.
    Bai X; Wilson KL; Seedorff JE; Ahrens D; Green J; Davison DK; Jin L; Stanfield-Oakley SA; Mosier SM; Melby TE; Cammack N; Wang Z; Greenberg ML; Dwyer JJ
    Biochemistry; 2008 Jun; 47(25):6662-70. PubMed ID: 18507398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.
    Dwyer JJ; Wilson KL; Davison DK; Freel SA; Seedorff JE; Wring SA; Tvermoes NA; Matthews TJ; Greenberg ML; Delmedico MK
    Proc Natl Acad Sci U S A; 2007 Jul; 104(31):12772-7. PubMed ID: 17640899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of the HIV-1 env genetic context outside HR1-HR2 on resistance to the fusion inhibitor enfuvirtide and viral infectivity in clinical isolates.
    Baatz F; Nijhuis M; Lemaire M; Riedijk M; Wensing AM; Servais JY; van Ham PM; Hoepelman AI; Koopmans PP; Sprenger HG; Devaux C; Schmit JC; Perez Bercoff D
    PLoS One; 2011; 6(7):e21535. PubMed ID: 21760896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41.
    Xu L; Pozniak A; Wildfire A; Stanfield-Oakley SA; Mosier SM; Ratcliffe D; Workman J; Joall A; Myers R; Smit E; Cane PA; Greenberg ML; Pillay D
    Antimicrob Agents Chemother; 2005 Mar; 49(3):1113-9. PubMed ID: 15728911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
    Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fusion intermediates of HIV-1 gp41 as targets for antibody production: design, synthesis, and HR1-HR2 complex purification and characterization of generated antibodies.
    Mzoughi O; Gaston F; Granados GC; Lakhdar-Ghazal F; Giralt E; Bahraoui E
    ChemMedChem; 2010 Nov; 5(11):1907-18. PubMed ID: 20922745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations of Glu560 within HIV-1 Envelope Glycoprotein N-terminal heptad repeat region contribute to resistance to peptide inhibitors of virus entry.
    Yuan C; Wang JY; Zhao HJ; Li Y; Li D; Ling H; Zhuang M
    Retrovirology; 2019 Dec; 16(1):36. PubMed ID: 31796053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The hydrophobic pocket contributes to the structural stability of the N-terminal coiled coil of HIV gp41 but is not required for six-helix bundle formation.
    Dwyer JJ; Hasan A; Wilson KL; White JM; Matthews TJ; Delmedico MK
    Biochemistry; 2003 May; 42(17):4945-53. PubMed ID: 12718536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 gp41 Residues Modulate CD4-Induced Conformational Changes in the Envelope Glycoprotein and Evolution of a Relaxed Conformation of gp120.
    Keller PW; Morrison O; Vassell R; Weiss CD
    J Virol; 2018 Aug; 92(16):. PubMed ID: 29875245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to N-peptide fusion inhibitors correlates with thermodynamic stability of the gp41 six-helix bundle but not HIV entry kinetics.
    De Feo CJ; Wang W; Hsieh ML; Zhuang M; Vassell R; Weiss CD
    Retrovirology; 2014 Oct; 11():86. PubMed ID: 25274545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selection with a peptide fusion inhibitor corresponding to the first heptad repeat of HIV-1 gp41 identifies two genetic pathways conferring cross-resistance to peptide fusion inhibitors corresponding to the first and second heptad repeats (HR1 and HR2) of gp41.
    Wang W; De Feo CJ; Zhuang M; Vassell R; Weiss CD
    J Virol; 2011 Dec; 85(24):12929-38. PubMed ID: 21994458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil.
    Champagne K; Shishido A; Root MJ
    J Biol Chem; 2009 Feb; 284(6):3619-27. PubMed ID: 19073602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients.
    Labrosse B; Morand-Joubert L; Goubard A; Rochas S; Labernardière JL; Pacanowski J; Meynard JL; Hance AJ; Clavel F; Mammano F
    J Virol; 2006 Sep; 80(17):8807-19. PubMed ID: 16912327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization.
    Reeves JD; Lee FH; Miamidian JL; Jabara CB; Juntilla MM; Doms RW
    J Virol; 2005 Apr; 79(8):4991-9. PubMed ID: 15795284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Designing a soluble near full-length HIV-1 gp41 trimer.
    Gao G; Wieczorek L; Peachman KK; Polonis VR; Alving CR; Rao M; Rao VB
    J Biol Chem; 2013 Jan; 288(1):234-46. PubMed ID: 23184960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and properties of N(CCG)-gp41, a chimeric gp41 molecule with nanomolar HIV fusion inhibitory activity.
    Louis JM; Bewley CA; Clore GM
    J Biol Chem; 2001 Aug; 276(31):29485-9. PubMed ID: 11418583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.